Unit of Neurology, G.B. Morgagni - L. Pierantoni Civic Hospital, Forlì.
Department of Medicine and Surgery, Kore University of Enna, Enna.
Int Clin Psychopharmacol. 2024 May 1;39(3):127-138. doi: 10.1097/YIC.0000000000000532. Epub 2023 Dec 27.
Nearly one-third of all stroke patients develop depression at any time after a stroke, and its presence is associated with unfavorable outcomes. This narrative review aims to provide a synopsis of possible pharmacological and non-pharmacological treatment modalities for post-stroke depression (PSD). Several studies have demonstrated the efficacy and safety of selective serotonin reuptake inhibitors in treating the symptoms of this clinical condition. The treatment of PSD has been recently enhanced by innovative approaches, such as cognitive-behavioral therapy, virtual reality, telehealth, repetitive transcranial magnetic stimulation, and non-conventional therapies, which might improve depression treatment in stroke survivors. Future high-quality randomized controlled trials are necessary to confirm this hypothesis.
近三分之一的脑卒中患者在脑卒中后任何时间都会出现抑郁,且其存在与不良结局相关。本综述旨在概述脑卒中后抑郁(PSD)可能的药物和非药物治疗方法。多项研究已经证实了选择性 5-羟色胺再摄取抑制剂治疗这种临床病症的症状的疗效和安全性。创新性方法如认知行为疗法、虚拟现实、远程医疗、重复经颅磁刺激和非传统疗法最近已经增强了 PSD 的治疗,这可能会改善脑卒中幸存者的抑郁治疗效果。需要未来开展高质量的随机对照试验来证实这一假设。